Delcath Systems FY2029 EPS Forecast Reduced by HC Wainwright

Delcath Systems, Inc. (NASDAQ:DCTH) – Analysts at HC Wainwright cut their FY2029 earnings per share estimates for shares of Delcath Systems in a research note issued on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $1.92 per share for the year, down from their previous estimate of $2.21. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ FY2030 earnings at $2.68 EPS.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. The company had revenue of $20.73 million for the quarter, compared to analyst estimates of $20.35 million. Delcath Systems had a return on equity of 2.70% and a net margin of 3.17%.

Several other research analysts have also issued reports on DCTH. Evercore set a $27.00 price target on shares of Delcath Systems in a research note on Thursday, February 26th. Wall Street Zen lowered shares of Delcath Systems from a “buy” rating to a “hold” rating in a report on Saturday. BTIG Research cut their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Stephens reduced their price objective on Delcath Systems from $25.00 to $18.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Delcath Systems in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Delcath Systems Trading Down 3.7%

Shares of Delcath Systems stock opened at $8.60 on Tuesday. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $18.23. The firm has a market capitalization of $298.85 million, a P/E ratio of 122.86 and a beta of 0.38. The business has a fifty day simple moving average of $9.93 and a two-hundred day simple moving average of $10.17.

Institutional Trading of Delcath Systems

Several institutional investors have recently added to or reduced their stakes in DCTH. California State Teachers Retirement System purchased a new position in shares of Delcath Systems in the second quarter worth $26,000. Russell Investments Group Ltd. bought a new stake in Delcath Systems in the 3rd quarter worth about $29,000. Tower Research Capital LLC TRC purchased a new position in Delcath Systems in the 2nd quarter worth about $40,000. Ameritas Investment Partners Inc. bought a new position in Delcath Systems during the 2nd quarter valued at about $42,000. Finally, Legal & General Group Plc bought a new position in Delcath Systems during the 2nd quarter valued at about $46,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems announced that its Board of Directors has initiated a share repurchase plan on Thursday, November 20th that authorizes the company to buyback $25.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 8.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.